Puretech Health Stock Price, News & Analysis

PureTech Health (LSE: PRTC, NASDAQ: PRTC) announced the appointment of George Farmer, Ph.D. as its new Chief Financial Officer. Dr. Farmer brings over 15 years of experience as a senior biotechnology equity analyst at BMO Capital Markets, where he provided extensive sector research. This leadership change comes as PureTech aims to capitalize on recent momentum, having initiated three clinical trials and expanded its presence in the NASDAQ Global Market.

PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) announced participation in the 38th Annual J.P. Morgan Healthcare Conference and other virtual events. Key presentations will include Daphne Zohar, CEO, on January 14, 2021, at 10:50am EST, and Bharatt Chowrira, J.D., Ph.D., alongside Eric Elenko, Ph.D., on January 5, 2021, at 1:00pm EST. PureTech focuses on developing innovative therapies for serious diseases, with a pipeline of 24 product candidates, two already cleared by the FDA. For more, visit puretechhealth.com.

PureTech Health (PRTC) has launched a Phase 1 clinical trial for LYT-200, targeting metastatic solid tumors resistant to current treatments. This monoclonal antibody aims to inhibit galectin-9, a protein that promotes tumor immunosuppression. The trial's primary goal is to assess safety and efficacy in escalating doses, with topline results expected in Q4 2021. Success in this trial could pave the way for a subsequent Phase 2 study exploring LYT-200’s potential in combination therapies.

PureTech Health (LSE: PRTC, Nasdaq: PRTC) announced the initiation of a Phase 2a proof-of-concept study for LYT-100 in patients with breast cancer-related upper limb secondary lymphedema. This chronic condition currently lacks FDA-approved drug therapies. LYT-100 aims to address inflammation and fibrosis, with a favorable safety profile from prior studies. The study plans to enroll up to 50 patients, focusing on safety and tolerability, with results expected in Q4 2021. This initiative highlights the urgent need for effective treatments for lymphedema, potentially positioning PureTech as a leader in this overlooked area.

Follica announced encouraging results from a pilot study on treating female pattern hair loss (FPHL) using its proprietary Hair Follicle Neogenesis (HFN) device. Enrolling 11 women, the study demonstrated significant hair growth over four months, with all participants reporting improvements. The device stimulates stem cells to develop new hair follicles, complemented by a topical drug. Despite the small sample size, the outcomes highlight a notable treatment gap for women with few options available. Follica plans to advance to Phase 3 development in 2021, furthering its commitment to innovative hair loss solutions.

Follica, a biotechnology firm focused on treating hair loss, announced positive results from a pilot study published in the International Journal of Women’s Dermatology. The study, led by Dr. Maryanne M. Senna, involved 11 women with female pattern hair loss (FPHL), showing significant hair growth after six treatments using the proprietary Hair Follicle Neogenesis (HFN) device. All participants reported improvement on the physician-assessed Sinclair scale. Follica aims to advance to Phase 3 trials in 2021, following successful studies in treating male androgenetic alopecia.

PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) noted the publication of a pilot study by its Founded Entity, Follica, in the International Journal of Women’s Dermatology. The study evaluated a treatment that promoted hair growth in women with female pattern hair loss (FPHL). Out of 11 participants, 10 reported improvements in hair growth after six treatments using Follica's proprietary Hair Follicle Neogenesis (HFN) device. The pilot study's results are viewed as encouraging, suggesting the need for larger studies to validate the findings.

PureTech Health (LSE: PRTC, Nasdaq: PRTC) has initiated a global Phase 2 trial for LYT-100, aimed at treating Long COVID respiratory complications. The trial follows a successful Phase 1 study demonstrating LYT-100's tolerability and favorable pharmacokinetic profile. LYT-100, a deuterated form of pirfenidone, targets inflammation and fibrosis associated with lung conditions, including Long COVID. The Phase 2 trial will assess efficacy, safety, and tolerability in adults, with results expected in the latter half of 2021. This research addresses a critical public health need as many COVID-19 survivors continue to experience respiratory issues.

PureTech Health (LSE: PRTC, Nasdaq: PRTC) is hosting its inaugural R&D Day on December 11, 2020, at 9:00 a.m. ET. This virtual event will highlight the company's advancements in lymphatics and immune pathways, featuring insights on its product candidates LYT-100 and LYT-200. Experts, including renowned scientists and physicians, will present their perspectives on fibrotic, inflammatory conditions, and immuno-oncology. The event aims to showcase PureTech's innovative therapeutic approaches and progress within its Wholly Owned Pipeline, which includes four product candidates.